Skip to main content
. Author manuscript; available in PMC: 2011 Mar 23.
Published in final edited form as: Nat Med. 2009 Jul 26;15(8):921–929. doi: 10.1038/nm.2001

Figure 6. F(ab′)2 therapy alters VAT resident macrophage phenotype.

Figure 6

a) MMRhi (%, upper gate), MMRlo (middle gate), and MMR− (lower gate) macrophages from VAT of 16 wk old HFD or lean NCD B6 mice (representative data from 4 similar experiments). b) IL-10 (left panel), MCP-1 (middle panel) and TNFα (right panel) produced by LPS stimulated, F4/80+ macrophages sorted from VAT of HFD (top panel) or NCD (lower panel) mice into MMR−, MMRlo, and MMRhi cell populations (one of 4 similar experiments). We consistently failed to obtain sufficient cell numbers for analysis of MMR− macrophages from VAT from lean mice. c) FACS plots from 2 independent experiments, measuring MMR expression in F4/80+ macrophages from HFD B6 VAT, 6 wk post F(ab′)2. d) IL-10 (left panel), MCP-1 (middle panel) and TNFα (right panel) produced by LPS stimulated F4/80+ macrophages sorted from VAT 6 wk post F(ab′)2 (n=3/group, *p<0.05, t-test).